Oncoinvent Asa · OSL:ONCIN
Oncoinvent Asa — Q4 2024 Earnings Presentation
28 slides from Oncoinvent Asa's earnings presentation, Nov 1, 2024
Slide 1: Oncoinvent
Oncoinvent Transforming cancer care through direct alpha therapy Targeting by proximity, brilliant in its simplicity
Slide 2: Highlights / Financials / Company Presentation
Highlights Financials Company Presentation
Slide 3: Recent Highlights
Recent Highlights Executed significant cost saving initiatives (2H) Hired Øystein Soug as new CEO (September) Corporate Raised NOK 141m in a private placement Listed for trading at Euronext Growth Oslo Entered into collaboration agreement with ARTBIO Reported preliminary promising signal of efficacy
Slide 4: Phase 2 study in ovarian cancer – enrollment started
PHASE 2 PROGRAM Ovarian cancer Phase 2 study in ovarian cancer – enrollment started All 6 centers active Patients • with primary advanced PFS pPFS HRD negative ovarian SoC+ Radspherin Assessment OS cancer Randomised (60 patients) every 3 months TFST Safety run-in • with peritoneal (6 patients) cohor
Slide 5: In-house GMP laboratory with attractive capabilities and capacity
MANUFACTURING AND SUPPLY In-house GMP laboratory with attractive capabilities and capacity Oncoinvent has in-house GMP 224Ra produced from 228Th, which Microparticles and finished goods production capability has multiple sources produced in-house Capacity of ~200 doses Radspherin annually, outsourci
Slide 6: Highlights / Financials / Company Presentation
Highlights Financials Company Presentation
Slide 7: Tuning expenses with a stronger focus on Radspherin in 2H 2024
Tuning expenses with a stronger focus on Radspherin in 2H 2024 2024 2023 2024 2023 GMP laboratory facilities: AMOUNTS IN 1 000 NOK NOTE Q4 Q4 Cange (+/-) 01.01.-31.12 01.01.-31.12 Cange (+/-) • Signed agreement with a (unaudited) (unaudited) (unaudited) (audited) Operating revenues duration from Dec
Slide 8: Quarterly presentations and IR conferences
Quarterly presentations and IR conferences 2025-02-27 Fourth quarter 2024 Report 2025-02-28 B. Riley Securities Precision Oncology & Radiopharma Conference 2025-03-05 TD Cowen Health Care Conference 2025-03-11 Carnegie Healthcare Seminar 2025-03-19 Bio Europe Spring 2025-04-28 Annual report 2024 202
Slide 9: Highlights / Financials / Company Presentation
Highlights Financials Company Presentation
Slide 10: Peritoneal metastases - urgent need for novel treatments
Peritoneal metastases - urgent need for novel treatments • Peritoneal metastases arise from many different primary cancers, amongst others ovarian and colorectal • Peritoneal metastases are confined to the peritoneum - the membrane covering the abdominal cavity and organs – creating a ‘closed compar
Slide 11: Radspherin® - innovative alpha emitting therapy targeted to and retained in the peritoneum
UNMET MEDICAL NEED AND TREATMENT CONCEPT Radspherin® - innovative alpha emitting therapy targeted to and retained in the peritoneum Radspherin® • Combining alpha-emitting 224Ra with CaCO3 microparticles • Delivering a high dose of alpha-radiation directly to the peritoneum through an in- dwelling ca
Slide 12: Radspherin® - innovative alpha emitting therapy targeted to and retained in the peritoneum
UNMET MEDICAL NEED AND TREATMENT CONCEPT Radspherin® - innovative alpha emitting therapy targeted to and retained in the peritoneum Radspherin® How does it work? • Combining alpha-emitting 224Ra with • Administration 1-3 days post-surgery CaCO3 microparticles • 75% of radiation dose delivered the fi
Slide 13: Radiopharmaceutical expertise at all levels
EXECUTIVE SUMMARY Radiopharmaceutical expertise at all levels Management Øystein Soug Gro Hjellum Anne-Kirsti Aksnes Kari Myren Tore Kvam Kristine Lofthus Stian Brekke Chief Executive Officer Chief Operations Officer Chief Clinical Officer Chief Medical Officer Chief Financial Officer Chief Producti
Slide 14: While the radiopharma sector is largely concentrated in two indications, Oncoinvent pursues peritoneal metastases
EXECUTIVE SUMMARY While the radiopharma sector is largely concentrated in two indications, Oncoinvent pursues peritoneal metastases Snapshot of the Radiopharma Landscape 224Ra 212Pb 225Ac 177Lu Other Commentary metastases Peritoneal • The Radspherin® approach harness the key advantages of radiopharm
Slide 15: Pipeline in one product - broad clinical application
UNMET MEDICAL NEED AND TREATMENT CONCEPT Pipeline in one product - broad clinical application Extraperitoneal Intraperitoneal metastases metastases Lung cancer Cholangiocarcinoma Breast cancer Gastric cancer • Peritoneal metastases arise from many Malignant melanoma Pancreatic cancer different cance
Slide 16: The main cause of death in ovarian cancer
UNMET MEDICAL NEED AND TREATMENT CONCEPT The main cause of death in ovarian cancer • Despite a comprehensive treatment approach, the majority of patients experience disease recurrence • Ovarian cancer rarely metastasize hematogenously, recurrences almost exclusively confined to the peritoneum • Need
Slide 17: Clinical development plan
Clinical development plan 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 Ovarian Survival follow-up Ph 1/2a Colorectal Ovarian N = 96 Ph 2 Colorectal TBD Ovarian Ph 3 = Interim read-out = Final results 17
Slide 18: Peritoneal control in colorectal cancer
PHASE 1/2A RESULTS Colorectal cancer Peritoneal control in colorectal cancer 18 months data from 20 of 36 patients receiving 7 MBq dose vs historical recurrence rates Peritoneal recurrence rate Radspherin® Historical control 15 % 50 % 15% >50% Peritoneal recurrence rate Peritoneal recurrence rate Fr
Slide 19: Peritoneal control in colorectal cancer
PHASE 1/2A RESULTS Colorectal cancer Peritoneal control in colorectal cancer 18 months data from 20 of 36 patients receiving 7 MBq dose vs historical recurrence rates Peritoneal recurrence rate Overall recurrence rate Radspherin® Historical control Radspherin® Historical control 15 % 50 % 50 % 70 %
Slide 20: Encouraging signal of efficacy in phase 1 in ovarian cancer
PHASE 1 RESULTS Ovarian cancer Encouraging signal of efficacy in phase 1 in ovarian cancer 12 months data from 10 patients receiving 7 MBq dose vs historical recurrence rate Peritoneal recurrence rate Overall recurrence rate Radspherin® Historical control Radspherin® Historical control 10 % 10 % 25
Slide 21: Safety profile validated in two phase 1/2a studies treating 68 patients
PHASE 1/2A RESULTS Safety profile validated in two phase 1/2a studies treating 68 patients • No dose limiting toxicity Well tolerated and safe to use • Only two out of 40 serious adverse events reported as possibly related to Radspherin* • Majority of radiation dose retained in the peritoneal cavity
Slide 22: Peritoneal metastases represent a significant market opportunity
EXECUTIVE SUMMARY Peritoneal metastases represent a significant market opportunity Adds perfectly to existing patient flow Limited competition High addressable patient number • Surgery is and will remain the cornerstone • Distinguished by its unique mechanism of • Total treatments per year targeted
Slide 23: Transforming cancer care through direct alpha therapy
SUMMARY Transforming cancer care through direct alpha therapy 1 High unmet need and limited competition 1 2 Compatible with established treatment regimes - adds well to existing patient flow 2 3 3 Targeted, non-biological, receptor independent mode of action with alpha emitter 4 4 Signals of efficac
Slide 24: Financials
OnNCO invent Financials
Slide 25: Statement of profit and loss and comprehensive income
Statement of profit and loss and comprehensive income 25
Slide 26: Statement of financial position
Statement of financial position NOTE 31.12.2024 31.12.2023 NOTE 31.12.2024 31.12.2023 (unaudited) (audited) (unaudited) (audited) ASSETS EQUITY AND LIABILITIES NON-CURRENT ASSETS EQUITY Land, Buildings and other property 3 839 7 335 Paid-in capital Equipment, machinery etc. 16 764 21 435 Share capit
Slide 27: Statement of cash flows
Statement of cash flows OnCco invent 2028 23 2008 2023 AMOUNTS IN NOK ‘000 aa aa Year Year (unaudited) (unaudited) (unaudited) _(audted) Profit loss) before tax (2705) (41.270) (140.201) (143621) Adjustments to reconcile profit before tax to net cash flow: Depreciation and amortization 2315 2361 920
Slide 28: Radspherin® - in development for two indications
CLINICAL DEVELOPMENT PROGRAM Radspherin® - in development for two indications Patients undergoing surgical resection for peritoneal metastases Ovarian cancer Colorectal cancer Phase 1: after surgical treatment of platinum-sensitive Phase 1/2a: after surgery and HIPEC in patients with recurrence sync